Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LRMR OTCMKTS:SEOVF NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$3.45-3.4%$4.41$1.80▼$6.42$358.40M0.911.86 million shs1.13 million shsSEOVFSernova Biotherapeutics$0.11-5.4%$0.12$0.09▼$0.16$41.09M0.8622,354 shs2,023 shsTLSATiziana Life Sciences$1.48+1.4%$1.32$1.14▼$2.60$188.34M0.42210,940 shs575,559 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics0.00%-3.63%-23.33%+16.16%+78.76%SEOVFSernova Biotherapeutics0.00%-7.56%-16.31%+6.04%-28.42%TLSATiziana Life Sciences0.00%+8.03%+20.33%+15.63%+4.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$3.45-3.4%$4.41$1.80▼$6.42$358.40M0.911.86 million shs1.13 million shsSEOVFSernova Biotherapeutics$0.11-5.4%$0.12$0.09▼$0.16$41.09M0.8622,354 shs2,023 shsTLSATiziana Life Sciences$1.48+1.4%$1.32$1.14▼$2.60$188.34M0.42210,940 shs575,559 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics0.00%-3.63%-23.33%+16.16%+78.76%SEOVFSernova Biotherapeutics0.00%-7.56%-16.31%+6.04%-28.42%TLSATiziana Life Sciences0.00%+8.03%+20.33%+15.63%+4.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLRMRLarimar Therapeutics 3.10Buy$16.33373.43% UpsideSEOVFSernova Biotherapeutics 0.00N/AN/AN/ATLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TLSA, LRMR, and SEOVF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $12.005/6/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026LRMRLarimar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026LRMRLarimar Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/20/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $13.003/3/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$11.00 ➝ $12.002/25/2026LRMRLarimar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $14.002/25/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.002/24/2026LRMRLarimar Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLRMRLarimar TherapeuticsN/AN/AN/AN/A$1.52 per shareN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/A($0.05) per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%N/ASEOVFSernova Biotherapeutics-$11.24M-$0.04N/AN/AN/AN/AN/A-761.41%6/11/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/A6/18/2026 (Estimated)Latest TLSA, LRMR, and SEOVF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026N/ASEOVFSernova Biotherapeutics-$0.0074N/AN/AN/AN/AN/A5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/A3/19/2026Q4 2025LRMRLarimar Therapeutics-$0.43-$0.73-$0.30-$0.73N/AN/A3/19/2026Q1 2026SEOVFSernova Biotherapeutics-$0.0073-$0.01-$0.0027-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLRMRLarimar TherapeuticsN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLRMRLarimar TherapeuticsN/A4.294.29SEOVFSernova BiotherapeuticsN/A0.030.03TLSATiziana Life SciencesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLRMRLarimar Therapeutics91.92%SEOVFSernova BiotherapeuticsN/ATLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipLRMRLarimar Therapeutics4.50%SEOVFSernova BiotherapeuticsN/ATLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionableSEOVFSernova BiotherapeuticsN/A377.64 millionN/ANot OptionableTLSATiziana Life Sciences8127.26 million76.58 millionOptionableTLSA, LRMR, and SEOVF HeadlinesRecent News About These CompaniesTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22 at 6:01 PM | proactiveinvestors.comTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22 at 5:06 PM | proactiveinvestors.comTiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment UpdateMay 21 at 5:38 PM | finance.yahoo.comTiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trialMay 21 at 11:47 AM | proactiveinvestors.comTiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialMay 21 at 11:00 AM | globenewswire.comTiziana Life Sciences price target boosted on foralumab updateMay 19, 2026 | proactiveinvestors.comTiziana says updated data for multiple sclerosis therapy shows long-term safetyMay 19, 2026 | seekingalpha.comTiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MSMay 19, 2026 | proactiveinvestors.comTiziana Life Sciences Ltd.: Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | finanznachrichten.deTiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | globenewswire.comTiziana Brain Trial Draws Fresh Nasdaq Index AttentionMay 16, 2026 | kalkinemedia.comKTiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trialMay 14, 2026 | proactiveinvestors.comTiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal ForalumabMay 14, 2026 | globenewswire.comTiziana Life Sciences Delays Annual 20-F FilingMay 2, 2026 | theglobeandmail.comTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and ...April 17, 2026 | finanznachrichten.deTiziana says intranasal drug shows potential to ease Long COVID “brain fog”April 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionApril 16, 2026 | globenewswire.comTiziana Life Sciences to present Phase 2a MSA study at World Parkinson CongressApril 14, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressApril 14, 2026 | globenewswire.comTiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingApril 1, 2026 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSA, LRMR, and SEOVF Company DescriptionsLarimar Therapeutics NASDAQ:LRMR$3.45 -0.12 (-3.36%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.64 +0.19 (+5.36%) As of 05/22/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Sernova Biotherapeutics OTCMKTS:SEOVF$0.11 -0.01 (-5.39%) As of 05/22/2026 02:59 PM EasternSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.Tiziana Life Sciences NASDAQ:TLSA$1.48 +0.02 (+1.37%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.52 +0.04 (+3.04%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
